



Jupiter Life Line Hospitals Limited

8th October, 2023

To,
National Stock Exchange of India Ltd.
Exchange Plaza, BKC
Bandra-Kurla Complex,
Bandra (East), Mumbai-400 051
Symbol: JLHL

To,
BSE Limited
P.J. Towers,
25th Floor, Dalal Street, Fort
Mumbai 400 001
Code: 543980

Subject: Intimation of Newspaper Publication for Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June 2023

Dear Sir/ Madam,

Pursuant to Regulations 30 and 47 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed a copy of newspaper publication in the following newspapers with respect to Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June 2023 approved at the meeting of Board of Directors held on Friday, 6th October 2023.

1. Financial Express
2. Pudhari Newspaper Marathi

This will also be posted on the Company's Website at www.jupiterhospital.com

You are requested to kindly take the afore mentioned on record and oblige.

Yours faithfully

For JUPITER LIFE LINE HOSPITALS LIMITED

Suma Upparatti
Company Secretary & Compliance Officer

Regd. Office:
1004, 10th Floor, 360 Degree Business Park,
Maharana Pratap Chowk, L.B.S. Marg,
Mulund (W), Mumbai - 400 080.

CIN: U85100MH2002PLC137908
GST No: 27AABCJ19821ZN
Email: info@jupiterhospital.com
Web: www.jupiterhospital.com

Thane:
Corporate Office: Eastern Express
Highway, Thane (W) 400 601.
☎ 022 2172 5585

Pune:
Baner, Pune 411 045.
☎ 020 2799 2211



JUPITER LIFE LINE HOSPITALS LIMITED

Registered Office: 1004, 10th Floor, 360 Degree Business Park, Maharana Pratap Chowk, LBS Marg, Mulund (West), Mumbai - 400 080, Maharashtra, India. Corporate Office: Jupiter Hospital, Eastern Express Highway, Thane (West), Mumbai - 400 601 Maharashtra, India. Telephone: +91 22 2172 5623; Email: investor.relations@jupiterhospital.com Website: www.jupiterhospital.com Corporate Identity Number: U85100MH2002PLC137908;

Extract of Unaudited Financial Results for the Period Ended 30th June, 2023

Sl. No.	Particulars	Standalone			Consolidated		
		Quarter ending 30th June 2023	Quarter ending 30th June 2022	Previous Year ending 31st March 2023	Quarter ending 30th June 2023	Quarter ending 30th June 2022	Previous Year ending 31st March 2023
		(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	2,078.73	1,789.23	7,873.22	2,432.22	2,005.62	8,525.48
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items#)	419.65	372.52	1,610.07	351.71	319.84	1,309.17
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary Items#)	406.05	372.52	1,588.82	337.61	319.78	1,287.08
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Items#)	304.40	371.61	1,072.34	539.97	304.46	729.05
5	Total Comprehensive Income for the Period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	325.65	371.61	1,078.80	561.72	304.46	731.06
6	Equity Share Capital	565.18	508.67	565.18	565.18	508.67	565.18
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.	4,410.71	3,073.44	4,085.06	3,635.15	2,551.92	3,073.92
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations) -						
	1. Basic:	5.76	7.31	20.58	9.99	5.99	13.95
	2. Diluted:	5.76	7.31	19.11	9.99	5.99	12.95

- The above Standalone and Consolidated Financial Results have been reviewed and approved by the Board of Directors at their meeting held on 6th October, 2023
- The above is extract of the detailed format of quarter ended results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015
- The Financial Results are prepared in accordance with the Companies (Indian Accounting Standards) Rule 2015 and amendments issued thereafter prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies as applicable
- Subsequent to the quarter ended 30th June, 2023, the Company has completed its Fresh initial public offer ("IPO") of 90,47,469 equity shares of face value of INR 10 each at an issue price of INR 735 per share (including share premium of INR 725 per share). This includes Pre-IPO Placement of 16,73,469 shares. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) w.e.f 18th September, 2023

**By order of the Board of Directors
For Jupiter Life Line Hospitals Limited
Dr. Ankit Thakker
Executive Director & CEO**

**Place : Mumbai
Date 6th October, 2023**

4

se

A

PLAT-
banned
channels
content,
channel

ing plat-
tivities to
t on Pri-
remove
terial in
ad chan-
1 abuse
total this
ydate on

ot share
1 groups
impact on

for Elec-
r Chan-
d that if
aries do
afe har-
of the IT
s, imply-
s can be
nder the
les even
ay have
hem.
se to the
commit-
nd ethi-
platform,
case of
lated to
(CP),
Material
id Gang
n accor-
; 2021.

.in

issioned
assembly line in the country

India for our global products airport," Trilokekar said.

MS
not
New
f on
The
bon
of U
und
04*
The
to d
The
On
Eng
The
(13)
Plo
Mh
in 1
ach
Ch
Pac
Dal
Pla

A
Line

E-A
Pac
nuc
Nof
Gua
Sec
Aut
on 1
Eig
(see
Share
Rate
BSE
Del
Al)
We
No
Ma
FI)
AT
loc
On
Mu
o15
Ho

to 1
The
EM
in 5
des
bar
bef
car
doc
Dat
For
in C
Sor
022
no.
wor
JP
Cen
089
Dab
Plea

JUPITER LIFE LINE HOSPITALS LIMITED

Registered Office: 1004, 10th Floor, 360 Degree Business Park, Maharana Pratap Chowk, LBS Marg, Mulund (West), Mumbai - 400 080, Maharashtra, India. Corporate Office: Jupiter Hospital, Eastern Express Highway, Thane (West), Mumbai - 400 601 Maharashtra, India. Telephone: +91 22 2172 5623; Email: investor.relations@jupiterhospital.com Website: www.jupiterhospital.com Corporate Identity Number: U85100MH2002PLC137908;

Extract of Unaudited Financial Results for the Period Ended 30th June, 2023

Amount In Millions (except per share data)

Sl. No.	Particulars	Standalone			Consolidated		
		Quarter ending 30th June 2023 (Unaudited)	Quarter ending 30th June 2022 (Unaudited)	Previous Year ending 31st March 2023 (Audited)	Quarter ending 30th June 2023 (Unaudited)	Quarter ending 30th June 2022 (Unaudited)	Previous Year ending 31st March 2023 (Audited)
1	Revenue from operations	2,078.73	1,789.23	7,873.22	2,432.22	2,005.62	8,925.43
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items#)	419.65	372.52	1,610.07	351.21	319.84	1,309.12
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary Items#)	406.05	372.52	1,588.82	337.61	319.78	1,287.08
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Items#)	304.40	371.61	1,072.14	539.97	304.46	729.05
5	Total Comprehensive Income fir the Period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	325.65	371.61	1,078.81	561.22	304.46	731.06
6	Equity Share Capital	565.18	508.67	565.18	565.18	508.67	565.18
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.	4,410.71	3,023.44	4,085.06	3,635.15	2,551.92	3,073.92
8	Earnings Per Share (of Rs.10/-each) (for continuing and discontinued operations) -						
	1. Basic:	5.76	7.31	20.58	9.93	5.99	13.95
	2. Diluted:	5.76	7.31	19.11	9.93	5.99	12.95

- The above Standalone and Consolidated Financial Results have been reviewed and approved by the Board of Directors at their meeting held on 6th October, 2023
- The above is extract of the detailed format of quarter ended results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and disclosure Requirements) Regulation 2015
- The Financial Results are prepared in accordance with the Companies (Indian Accounting Standards) Rule 2015 and amendments issued thereafter prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies as applicable
- Subsequent to the quarter ended 30th June, 2023, the Company has completed its Fresh initial public offer ("IPO") of 90,47,469 equity shares of face value of INR 10 each at an issue price of INR 735 per share (including share premium of INR 725 per share). This includes Pre-IPO Placement of 16,73,469 shares. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) w.e.f 18th September, 2023

**By order of the Board of Directors
For Jupiter Life Line Hospitals Limited**

**Dr. Ankit Thakker
Executive Director & CEO**

**Place : Mumbai
Date 6th October, 2023**